EBITDA beat 31%, CEM scaling strong; Dow R&D and semiconductors unmonetized, execution risk ahead

Q1 FY27 EBITDA margin 31% vs 30% Q1 FY26; +100 bps QoQ expansion

Q1 FY27 PAT 19% vs 18% Q1 FY26; PAT +33% YoY corroborates

Commissioned Feb 2026, profitable faster than planned; supporting Milliken supply agreement; enabling CEM mix shift

Started ₹45 Cr Q1 FY26, now Site 4 producing ~₹70 Cr with clear demand line of sight

R&D-stage only, no orders, no commercialization date ('multiyear', 'can't put date on it'). Potential real; monetization unproven.

Site 3 samples submitted, small orders in progress; Site 5 main 45 tons/month targeted end-Sep. Early stage, unqualified customers.

Prior: 'deepening relationships.' New: explicit 70%+ target in 'couple of years' with 10 new marquee clients Q1, order pipeline 'deepest ever.'

Announced 30-Jul, multiyear silicone manufacturing tech development. India-exclusive, no prior partnership of this scale in advanced materials.

Site 5 dedicated 400-ton capacity for low-dielectric 5G/AI materials, $50/kg, targeting 3x by 2030. Samples submitted, orders in progress.

Q1 FY26 start ₹45 Cr, now Site 4 producing ~₹70 Cr with clear demand line of sight. Oil & gas now 20% of revenue.

CEM mix shift contributing. No new numeric guidance stated; implied maintained with upside delivery.

Order book confidential for competitive reasons. Pursuing small high-value molecules, not broad range. Core process competencies directly apply.

Three products (pharma, agro, material science) at $30-40/kg. Pharma for cholesterol/triglyceride control. Confidential on product names.

Exclusive India-focused R&D program. Dow and Aether work together only on this specific silicone manufacturing tech in India.

Multiyear R&D, can't disclose investment size. R&D → pilot → potential commercial framework. $1B India silicones market, 7-10% CAGR. History with Dow opens future opportunities.

5G/AI hardware: silane coupling agents, PPE resins, low-dielectric formulations. 400 tons starting, 3x by 2030 at $50/kg. ISM 2.0 unclear structure; applying but can't promise.

Focus on CRAMS/CEM toward 70%+ revenue. Never lost LSM market share vs China despite cuts. Prices recovering; still competitive. LSM to be 35% future contribution.

Behind each announced customer (Baker Hughes, Milliken, Seqens, Dow, Polaroid, Otsuka), 4-5 others in various stages. NDAs complex; many announcements expected near/midterm.

LSM volume -22.5%, pricing +22.5%, reallocated to CEM in Site 3. No demand decline. CEM 28-30% margins higher than LSM.

Large part Baker Hughes, scaled from ₹45 Cr Q1 FY26 to ~₹70 Cr Site 4 now. Clear demand line of sight. Other O&G customers also serviced.

13-year partnership track record. Pragmatic approach; chose Site 5 location near Surat R&D. Techno-commercial promoter team aids rapid decisions. Top risks: (1) Safety. (2) Execution ability on complex innovations.

Q1 +27% YoY; if sustained 25-27% FY27 implies ~₹410-420 Cr full year. Depends on macro, Dow/semiconductor scaling.

Site 5 Phase 1 online, 45 tons/month targeted end-Sep. Customers pre-audited, demand lined up. But orders unqualified.

Multiyear R&D, pilot-to-commercial transition undefined. 'Can't put revenue date on this.' India $1B CAGR 7-10% addressable if tech succeeds.

Reiterated on call. Q1 company-wide 31% elevated by mix; expect normalization to band as CEM scales to 70%.

In line. Reaffirmed despite capex headwinds.

Management declined ('don't give product-specific margins'). Limits forecasting precision.

Site 5 expansion and new R&D facility (15 labs, 160 fume hoods, FY28 on track). Q1 ₹943 Cr capex consistent with full-year range.

Baker Hughes now ~₹70 Cr (~21% Q1 revenue), up from ₹45 Cr start. Oil & Gas ~31% of revenue. Single customer slowdown or renegotiation materially impacts topline and EBITDA.

Dow silicones R&D is multiyear, early-stage, with unproven manufacturing technology. No firm commercialization path, revenue timeline, or customer offtake. If tech fails to scale, significant capex sunk cost and strategic pivot required.

400-ton low-dielectric materials capacity is nascent. Only samples submitted, small orders progressing, no major customer POs disclosed. Site 5 Phase 1 capex (₹2.2-2.3B) underutilization risk if demand doesn't materialize.

Concurrent capex ₹3-3.5B FY27, R&D facility FY28, Dow R&D program, Site 5 ramp, CRAMS/CEM scaling, and semiconductor entry strain management team. Acknowledged but defended.

Chinese LSM competitors cut prices 30-35% post-COVID. While Aether claims no market share loss, sustained discounting could force margin concessions on remaining LSM business as it shrinks to 35% of revenue.